Patents by Inventor Everett Stone

Everett Stone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY
    Publication number: 20240091258
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: December 13, 2022
    Publication date: March 21, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George GEORGIOU, Everett STONE
  • Compositions Of Engineered Human Arginases And Methods For Treating Cancer
    Publication number: 20240009283
    Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.
    Type: Application
    Filed: January 26, 2023
    Publication date: January 11, 2024
    Applicant: Aerase, Inc.
    Inventors: George Georgiou, Everett Stone
  • NOVEL NICOTINE DEGRADING ENZYME VARIANTS
    Publication number: 20230416697
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Application
    Filed: March 2, 2023
    Publication date: December 28, 2023
    Applicants: Antidote Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Matthew W. KALNIK, Thomas THISTED, Everett STONE, Charles C. REED, Max RODNICK-SMITH
  • HUMAN KYNURENINASE ENZYMES AND USES THEREOF
    Publication number: 20230405049
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: April 6, 2023
    Publication date: December 21, 2023
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George GEORGIOU, Everett STONE, John BLAZECK, Christos KARAMITROS
  • ENZYME-MEDIATED DEPLETION OF ADENOSINE AND/OR METHYLTHIOADENOSINE
    Publication number: 20230227796
    Abstract: Methods and compositions related to the engineering of a protein with MTA/ADO-degrading enzyme activity are described. For example, in certain aspects there may be disclosed an MTase capable of degrading MTA/ADO. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer or SCID with an MTase using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: November 10, 2022
    Publication date: July 20, 2023
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Everett STONE, Donjeta GJUKA
  • Human kynureninase enzymes and uses thereof
    Patent number: 11648272
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: May 16, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, John Blazeck, Christos Karamitros
  • Nicotine degrading enzyme variants
    Patent number: 11597916
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 7, 2023
    Assignees: ANTIDOTE THERAPEUTICS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Matthew W. Kalnik, Thomas Thisted, Everett Stone, Charles C. Reed, Max Rodnick-Smith
  • Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
    Patent number: 11591579
    Abstract: Disclosed herein are compositions related to conjugated polypeptides with MTA/ADO-degrading enzyme activity. The conjugated polypeptides are engineered to allow for maximal conjugation while maintaining catalytic activities. Also disclosed are nucleic acids, expression vectors, and host cells related to the conjugated polypeptides. Further disclosed are methods of using the pharmaceutical formulations comprising above to treat cancer.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: February 28, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Everett Stone
  • Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
    Patent number: 11584949
    Abstract: Methods and composition related to the engineering of a novel protein with methionine-?-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-?-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: February 21, 2023
    Assignee: AEMASE, INC.
    Inventors: George Georgiou, Everett Stone
  • Human kynureninase enzyme variants having improved pharmacological properties
    Patent number: 11542486
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: January 3, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, John Blazeck
  • Nucleic acids encoding kynurenine depleting enzymes
    Patent number: 11534463
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: December 27, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone
  • ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY
    Publication number: 20220275099
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: October 11, 2021
    Publication date: September 1, 2022
    Inventors: George GEORGIOU, Everett STONE, Nicholas MARSHALL, John BLAZECK, Wei-Cheng LU
  • Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
    Patent number: 11426464
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-?-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: August 30, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone
  • Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
    Patent number: 11396647
    Abstract: Disclosed herein are compositions related to conjugated polypeptides with MTA/ADO-degrading enzyme activity. The conjugated polypeptides are engineered to allow for maximal conjugation while maintaining catalytic activities. Also disclosed are nucleic acids, expression vectors, and host cells related to the conjugated polypeptides. Further disclosed are methods of using the pharmaceutical formulations comprising above to treat cancer.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: July 26, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Everett Stone
  • HUMAN METHYLTHIOADENOSINE/ADENOSINE DEPLETING ENZYME VARIANTS FOR CANCER THERAPY
    Publication number: 20220047683
    Abstract: Disclosed herein are compositions related to conjugated polypeptides with MTA/ADO-degrading enzyme activity. The conjugated polypeptides are engineered to allow for maximal conjugation while maintaining catalytic activities. Also disclosed are nucleic acids, expression vectors, and host cells related to the conjugated polypeptides. Further disclosed are methods of using the pharmaceutical formulations comprising above to treat cancer.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 17, 2022
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Everett STONE
  • IMPROVED HUMAN METHYLTHIOADENOSINE/ADENOSINE DEPLETING ENZYME VARIANTS FOR CANCER THERAPY
    Publication number: 20220042001
    Abstract: Disclosed herein are compositions related to conjugated polypeptides with MTA/ADO-degrading enzyme activity. The conjugated polypeptides are engineered to allow for maximal conjugation while maintaining catalytic activities. Also disclosed are nucleic acids, expression vectors, and host cells related to the conjugated polypeptides. Further disclosed are methods of using the pharmaceutical formulations comprising above to treat cancer.
    Type: Application
    Filed: January 6, 2021
    Publication date: February 10, 2022
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Everett STONE
  • HUMAN-ENZYME MEDIATED DEPLETION OF HOMOCYSTEINE FOR TREATING PATIENTS WITH HYPERHOMOCYSTEINEMIA AND HOMOCYSTINURIA
    Publication number: 20210386838
    Abstract: Methods and compositions relating to the engineering of an improved protein with homocyst(e)inase enzyme activity are described. For example, there are disclosed modified cystathionine-?-lyase (CGL) enzymes comprising one or more amino acid substitutions and capable of degrading homocyst(e)ine. Furthermore, provided are compositions and methods for the treatment of homocystinuria or hyperhomocysteinemia with homocyst(e)ine depletion using the disclosed enzymes or nucleic acids.
    Type: Application
    Filed: May 25, 2021
    Publication date: December 16, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: George GEORGIOU, Everett STONE, Wei-Cheng LU
  • ENGINEERED PRIMATE CYSTINE/CYSTEINE DEGRADING ENZYMES FOR THERAPEUTIC USES
    Publication number: 20210380962
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, disclosed are modified cystathionine-?-lyases comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, compositions and methods are provided for the treatment of cystinuria using the disclosed modified enzymes or nucleic acids encoding said enzymes.
    Type: Application
    Filed: October 25, 2019
    Publication date: December 9, 2021
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Everett STONE, Wei-Cheng LU, Christos KARAMITROS
  • Administration of kynurenine depleting enzymes for tumor therapy
    Patent number: 11168142
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: November 9, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, Nicholas Marshall, John Blazeck, Wei-Cheng Lu
  • Enzyme-mediated depletion of adenosine and/or methylthioadenosine
    Patent number: 11118167
    Abstract: Methods and compositions related to the engineering of a protein with MTA/ADO-degrading enzyme activity are described. For example, in certain aspects there may be disclosed an MTase capable of degrading MTA/ADO. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer or SCID with an MTase using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: September 14, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Everett Stone, Donjeta Gjuka